Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Lidocaine 5% Plasters (Versatis® 5%) in Pediatric Neuropathic Pains and Vasoocclusive Sickle Cell Crisis Pains

This study has been completed.
Information provided by (Responsible Party):
Centre Leon Berard Identifier:
First received: March 11, 2011
Last updated: October 29, 2014
Last verified: October 2014